Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Cyteir Therapeutics, Inc. (CYTT) had Return on Tangible Equity of -31.49% for the most recently reported fiscal year, ending 2022-12-31.
| Income Statement Financials | |
-- |
|
$-46.06M |
|
-- |
|
-- |
|
$48.17M |
|
$-48.17M |
|
$2.11M |
|
$-46.06M |
|
$-46.06M |
|
$-46.06M |
|
$-46.06M |
|
$-46.06M |
|
$-46.06M |
|
$-48.17M |
|
$-47.50M |
|
35.27M |
|
35.27M |
|
$-1.31 |
|
$-1.31 |
|
| Balance Sheet Financials | |
$149.21M |
|
$1.70M |
|
$4.02M |
|
$153.23M |
|
$5.32M |
|
-- |
|
$1.63M |
|
$6.95M |
|
$146.29M |
|
$146.29M |
|
$146.29M |
|
35.52M |
|
| Cash Flow Statement Financials | |
$-42.53M |
|
$-0.31M |
|
$0.24M |
|
$189.98M |
|
$147.38M |
|
$-42.60M |
|
$4.68M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
28.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-42.84M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.49% |
|
|
Return on Tangible Equity |
-31.49% |
-30.06% |
|
-31.49% |
|
$4.12 |
|
$-1.21 |
|
$-1.21 |
|